T cells exhibit remarkable plasticity in the tumor microenvironment (TME), dynamically adapting their phenotypes and functions to influence cancer progression and treatment responses. A new review published in MedComm-Oncology systematically dissects the mechanisms underlying T-cell plasticity, including spatial distribution, metabolic reprogramming, and interactions with TME components. The study highlights how targeting T-cell plasticity could revolutionize cancer therapy by enhancing immunotherapy efficacy and overcoming treatment resistance.

Dana-Farber Cancer Institute researchers are leading four studies with compelling and potentially practice changing results in colorectal cancer and breast cancer.

Investigators will also present clinical trial results that support future research into new strategies for the treatment of rare and aggressive forms of cancer and new approaches to de-escalate treatment and improve quality of life.

A team of three Japanese researchers has conducted a survey of stakeholders to examine how patient voices impact decisions related to genetic testing for hereditary cancers. These stakeholders included patients, healthcare professionals, and ethicists attending a workshop in Hiroshima in early 2025.